-
公开(公告)号:EP3762058B1
公开(公告)日:2024-01-10
申请号:EP19763751.5
申请日:2019-03-06
发明人: RODEFELD, Mark, D.
IPC分类号: A61M1/00 , F04B17/00 , F04B35/02 , F04D7/02 , F04D13/04 , F04D29/22 , A61M60/148 , A61M60/232 , A61M60/35 , A61M60/405 , A61M60/806 , A61M60/861 , A61M60/882 , A61M60/82 , A61M60/824 , F04D29/043 , F04D29/046
-
公开(公告)号:EP3283472B1
公开(公告)日:2021-04-14
申请号:EP16780846.8
申请日:2016-04-15
IPC分类号: C07D401/04 , A01N43/54 , A61K31/496 , A61K31/506 , C07D213/74 , C07D239/47 , C07D413/04
-
公开(公告)号:EP3297623B1
公开(公告)日:2020-10-28
申请号:EP16796931.0
申请日:2016-05-05
发明人: KELLEY, Mark R. , FISHEL, Melissa
IPC分类号: A61K31/192 , A61K31/519 , A61K31/63 , A61K45/06 , A61K31/00 , A61K31/122 , A61P35/00
-
公开(公告)号:EP3696881A1
公开(公告)日:2020-08-19
申请号:EP20160559.9
申请日:2012-05-17
发明人: XIE, Jian
IPC分类号: H01M2/18 , H01M2/16 , H01M10/052 , B82Y30/00 , H01M4/1395 , H01M10/0566
摘要: A device for extending the life of a battery, including an electrode having a metal portion, wherein the metal portion is selected from the group including lithium, calcium, magnesium, sodium, potassium and combinations thereof, an electrolyte permeable membrane, and a metal dendrite seeding material disposed between the electrode and the membrane. The electrode, the membrane and the metal dendrite seeding material are positioned in an electrolyte matrix. At least one dendrite extends from the electrode toward the electrolyte permeable membrane combines with at least one dendrite extending from the dendrite seeding material.
-
公开(公告)号:EP3367467B1
公开(公告)日:2020-03-04
申请号:EP17203731.9
申请日:2012-05-17
发明人: XIE, Jian
IPC分类号: H01M2/18 , H01M2/16 , H01M10/052 , B82Y30/00 , H01M4/1395 , H01M10/0566
-
-
公开(公告)号:EP3520860A1
公开(公告)日:2019-08-07
申请号:EP19156166.1
申请日:2012-05-25
IPC分类号: A61P35/00 , C07D295/12 , A61K31/4412 , A61K31/496 , A61K31/5377 , C07D295/192 , C07D295/185
摘要: The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.
-
公开(公告)号:EP3380194A1
公开(公告)日:2018-10-03
申请号:EP16869113.7
申请日:2016-11-18
CPC分类号: A61K31/353 , A61K31/335 , A61K31/343 , A61K39/39541 , A61K2039/505 , A61P27/02
摘要: Compositions including the combination of cremastranone analogs and anti-angiogenic agents and the use of the compositions for targeting ocular angiogenesis such as seen in neovascular eye diseases are disclosed.
-
公开(公告)号:EP2672266B1
公开(公告)日:2018-08-01
申请号:EP13175642.1
申请日:2007-01-13
IPC分类号: G01N33/00 , G01N33/566 , G01N33/567 , G01N33/564 , G01N33/68
CPC分类号: G01N33/564 , G01N33/6887 , G01N2800/12
摘要: Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.
-
公开(公告)号:EP3313176A1
公开(公告)日:2018-05-02
申请号:EP16815387.2
申请日:2016-06-24
IPC分类号: A01K67/027 , A61K35/407 , C12N9/26 , C12N9/40 , C12N15/85 , C12N15/877
CPC分类号: A01K67/0275 , A01K2207/15 , A01K2217/075 , A01K2227/108 , A01K2267/025 , A61K35/407 , A61K35/44 , C07K14/705 , C12N15/8509 , C12N15/877
摘要: The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Transgenic pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.
-
-
-
-
-
-
-
-
-